Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 3Active not recruiting 3Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Laryngeal Diseases 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × monalizumab × Clear all
NCT04590963 2026-06-01

INTERLINK-1

AstraZeneca

Phase 3 Active not recruiting
370 enrolled 21 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT05221840 2026-05-18

PACIFIC-9

AstraZeneca

Phase 3 Active not recruiting
1,051 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

MedImmune LLC

Phase 1/2 Active not recruiting
383 enrolled 48 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡